Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Monaliben Patel"'
Autor:
Elisha Fredman, MD, Michael Kharouta, MD, Eric Chen, MD, Andrew Gross, MD, Jennifer Dorth, MD, Monaliben Patel, MD, Gil Padula, MD, Min Yao, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 7, Iss 6, Pp 101026- (2022)
Purpose: Patients with head and neck (H&N) and esophageal cancer are at high risk for treatment-related symptomatic dehydration, often leading to interventions and hospital admissions. We tested the hypothesis that preemptive daily oral hydration dur
Externí odkaz:
https://doaj.org/article/b3fa5ffa4b374e52a5c3a7747c5895ef
Autor:
Pingfu Fu, Anant Madabhushi, Quintin Pan, James Lewis, Reetoja Nag, Germán Corredor, Vidya Viswanathan, Jay Wasman, Theodoros Teknos, Monaliben Patel
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/ad8b73c1680e492b9c19ba6c0ca3f7f6
Autor:
Reshma Jagsi, Krithika Suresh, Chris D. Krenz, Rochelle D. Jones, Kent A. Griffith, Lydia Perry, Sarah T. Hawley, Brian Zikmund-Fisher, Kayte Spector-Bagdady, Jodyn Platt, Raymond De Vries, Angela R. Bradbury, Pranshu Bansal, Melissa Kaime, Monaliben Patel, Richard L. Schilsky, Robert S. Miller, Rebecca Spence
Publikováno v:
JCO Oncology Practice.
PURPOSE: CancerLinQ seeks to use data sharing technology to improve quality of care, improve health outcomes, and advance evidence-based research. Understanding the experiences and concerns of patients is vital to ensure its trustworthiness and succe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2d9f4e839d3cf7076a65fa88e35c46d
https://doi.org/10.1200/op.23.00080
https://doi.org/10.1200/op.23.00080
Autor:
Mitchell Machtay, Stanton L. Gerson, Monaliben Patel, David L. Bajor, Debora S. Bruno, Shufen Cao, Pingfu Fu, Shakun Malik, Nancy L. Oleinick, John J. Pink, Charles A. Kunos, Afshin Dowlati, Tithi Biswas
Purpose:TRC102, a small-molecule base-excision repair inhibitor, potentiates the cytotoxicity of pemetrexed and reverses resistance by binding to chemotherapy-induced abasic sites in DNA. We conducted a phase I clinical trial combining pemetrexed and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20ee52ebdeb49d0abe7e18d85aaed4c0
https://doi.org/10.1158/1078-0432.c.6531291.v1
https://doi.org/10.1158/1078-0432.c.6531291.v1
Autor:
Mitchell Machtay, Stanton L. Gerson, Monaliben Patel, David L. Bajor, Debora S. Bruno, Shufen Cao, Pingfu Fu, Shakun Malik, Nancy L. Oleinick, John J. Pink, Charles A. Kunos, Afshin Dowlati, Tithi Biswas
Supplementary Data from Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4154f925bb072fc0960c03a8ac23962e
https://doi.org/10.1158/1078-0432.22483995
https://doi.org/10.1158/1078-0432.22483995
Autor:
Pingfu Fu, Monaliben Patel, John J. Pink, Tithi Biswas, Mitchell Machtay, Shufen Cao, Charles A Kunos, Debora S. Bruno, Stanton L. Gerson, David L. Bajor, Nancy L. Oleinick, Shakun Malik, Afshin Dowlati
Publikováno v:
Clin Cancer Res
Purpose: TRC102, a small-molecule base-excision repair inhibitor, potentiates the cytotoxicity of pemetrexed and reverses resistance by binding to chemotherapy-induced abasic sites in DNA. We conducted a phase I clinical trial combining pemetrexed an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ad685249764bb7df5be0c6d6832b2e0
https://doi.org/10.1158/1078-0432.ccr-21-2025
https://doi.org/10.1158/1078-0432.ccr-21-2025
Publikováno v:
JCO precision oncology. 6
PURPOSE Comprehensive tumor biomarker testing is a fundamental step in the selection of highly effective molecularly driven therapies for a variety of solid tumors. The primary objective of this study was to examine racial differences in biomarker te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39f5f75ac5e3a88487f5f248d25da5f1
https://pubmed.ncbi.nlm.nih.gov/35737912
https://pubmed.ncbi.nlm.nih.gov/35737912
Publikováno v:
Expert Review of Anticancer Therapy. 20:675-686
The treatment of stage III non-small cell lung cancer (NSCLC) remains challenging and associated with overall poor outcomes. Since seminal studies in the early 90s introduced concurrent chemo-radiotherapy as standard of care for treatment of this dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::517e47c226d7548310a1b4cab10cbd09
https://doi.org/10.1080/14737140.2020.1796645
https://doi.org/10.1080/14737140.2020.1796645
Publikováno v:
Current treatment options in oncologyReferences and Recommended ReadingPapers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance. 22(7)
Advanced non-melanoma skin cancers have been challenging to treat due to limited treatment options. Treatment paradigm has shifted with the approval of immunotherapeutic agents cemiplimab and pembrolizumab which have been a key development and have c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::425b7f2eed0129cdb82a39433f2d3541
https://pubmed.ncbi.nlm.nih.gov/34097150
https://pubmed.ncbi.nlm.nih.gov/34097150
Autor:
K.V. Chaung, M.Z. Kharouta, Pierre Lavertu, Monaliben Patel, Nicole Fowler, Min Yao, Rod Rezaee
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e409
PURPOSE/OBJECTIVE(S) The American Joint Committee on Cancer (AJCC) introduced the 8th edition staging for cancer in 2017, which provided separate staging for HPV+ oropharyngeal cancer (OPC). This update simplified staging with the intent of restoring
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54f72048fd372e1af13885dbd431ad06
https://doi.org/10.1016/j.ijrobp.2021.07.1177
https://doi.org/10.1016/j.ijrobp.2021.07.1177